吉西他滨联合唑来膦酸治疗乳腺癌多发骨转移临床疗效分析  

Analysis on Clinical Efficacy of Gemcitabine Combined with Zoledronic Acid in Treatment of Breast Cancer with Multiple Bone Metastases

作　　者：杨保庆[1] 车建华[1] 杨玲玲[1] 潘海波[1] 

机构地区：[1]广西壮族自治区钦州市第一人民医院肿瘤一区,广西钦州535000

出　　处：《肿瘤防治研究》2012年第10期1258-1260,共3页Cancer Research on Prevention and Treatment

摘　　要：目的观察吉西他滨联合唑来膦酸治疗乳腺癌多发骨转移的疗效及安全性。方法采用随机对照研究,52例乳腺癌多发骨转移分为治疗组与对照组,治疗组28例吉西他滨联合唑来膦酸;对照组24例单纯吉西他滨治疗;比较和分析治疗结果。结果两组治疗的有效率、临床获益率(CR+PR+SD≥6月)分别为50.0%、67.9%和45.8%、54.2%;两组近期疗效、生活质量改善及不良反应比较,差异无统计学意义(P>0.05)。治疗组骨痛缓解率是78.5%,高于对照组(45.8%),差异有统计学意义(χ2=5.97,P<0.05)。结论吉西他滨联合唑来膦酸治疗乳腺癌多发骨转移具有协同效应,骨痛缓解、提高生活质量明显,不良反应可耐受。Objective To investigate the efficacy and safety of gemcitabine combined with zoledronic acid in treatment of breast cancer patients with multiple bone metastases. Methods The randomized, controlled method was adopted. Fifty-two breast cancer patients with multiple bone metastases were randomly assigned to trial group （28 cases）and control group（24 cases）,the trial group was administered with gem citabine plus zoledronic acid and the control group was administered with gemcitabine alone. The effect in the two groups was compared. Results The over all response and the clinical benefit rate（CR ＋ PR ＋ SD ≥6 months）of the trial group was 50.0% and 67.9% ,and the control group was 45.8% and 54.2% ,re spectively. The curative effeiciency,improvement in quality of life, and toxic side effects between the two groups had no significant difference. Relief of bone pain was 78.5% in trial group,which was significantly higher than that in control group （45.8 5 ）, there was statistic difference（X2 = 5.97, P〈0.05 ）. Conclusion Gemeitabine combined with Zoledronic acid for breast cancer patients with bone metastases has synergis tic effect and favorable therapeutic efficacy and relief of bone pain and improving quality of life. The adverse effects is well tolerated.

关 键 词：乳腺肿瘤 吉西他滨 唑来膦酸 

分 类 号：R737.9[医药卫生—肿瘤]